Cervical cancer is the fourth leading cause of cancer deaths in women worldwide. Although the disease is driven by two antigenic viral oncoproteins, therapeutic vaccines have proved ineffective, ...

AbstractPurpose:. The incidence of human papillomavirus (HPV)–associated head and neck squamous cell carcinoma (HPV + HNSCC) is increasing in the United States. Currently, there are no early detection ...

LINE-1 ORF1p binds viral-like repeat RNAs, which when suppressed activate innate immune responses that change cell plasticity, reduce tumor cell growth, and alter the surrounding microenvironment in ...

AbstractPurpose:. Targeted tumor delivery may be required to potentiate the clinical benefit of innate immune modulators. The objective of the study was to apply an antibody–drug conjugate (ADC) ...

A longitudinal clinical study using intraoperative 13C-glucose infusions in patients with non–small cell lung cancer finds that use of glucose by tumors to supply the tricarboxylic acid cycle predicts ...

We evaluate cancer-protective effects of walnuts via formation of microbe-derived urolithin A, substantiating their functional benefits on serum inflammatory markers and immunologic composition of ...

BBO-8520, a dual inhibitor of KRASG12C in its GTP- and GDP-bound states, has a novel mechanism of action that enables effector blockade and optimal target coverage, even in growth factor activated ...

Zongertinib, a covalent HER2 inhibitor, is active in HER2-driven preclinical models and patients and effectively targets HER2 oncogenic signaling while sparing wild-type EGFR, resulting in potent ...

ROPN1 is a highly expressed intracellular antigen in triple-negative breast cancer, and a T-cell receptor targeting ROPN1 enables sensitive and selective cancer cell recognition, supporting use as a ...

Tumor cell-derived signals induce stromal IL33 expression in pancreatic cancer and stromal IL33 promotes pancreatic cancer growth by supporting immunosuppression.

Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER +), HER2 ...

AbstractPurpose:. Posttreatment detection of ctDNA is strongly predictive of recurrence. Most minimal/molecular residual disease assays require prior tissue testing to guide ctDNA analysis, resulting ...